HPV and HPV-associated diseases

Infectious Disease Clinics of North America

Volumn 27, Issue 4, 2013, Pages 765-778

  Dunne, Eileen F ^a   Park, Ina U ^b,c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c California STD/HIV Prevention Training Center   (United States)

Author keywords

Anogenital warts; Cervical cancer; Genital warts; HPV; HPV vaccines; HPV associated diseases

Indexed keywords

CAPSID PROTEIN L1; CIDOFOVIR; DICHLOROACETIC ACID; FLUOROURACIL; GREEN TEA EXTRACT; IMIQUIMOD; PLACEBO; PODOPHYLLOTOXIN; TRICHLOROACETIC ACID; WART VIRUS VACCINE;

ANUS CANCER; CANCER CONTROL; CANCER PREVENTION; CANCER SCREENING; CLINICAL FEATURE; COLPOSCOPY; CONDYLOMA ACUMINATUM; CRYOTHERAPY; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DRUG EFFICACY; EPIDEMIOLOGICAL DATA; ERYTHEMA; HIGH RESOLUTION ANOSCOPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYSTERECTOMY; IMMUNOCOMPROMISED PATIENT; INCIDENCE; INJECTION SITE PAIN; MULTIPLE CYCLE TREATMENT; OROPHARYNX CANCER; PAPILLOMATOSIS; PAPILLOMAVIRUS INFECTION; PENIS CANCER; PHOTODYNAMIC THERAPY; RECTUM ABDOMINOPERINEAL RESECTION; RECTUM BIOPSY; RECTUM SURGERY; REVIEW; RISK FACTOR; SWELLING; SYSTEMATIC REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CONIZATION; VAGINA CANCER; VIRUS TRANSMISSION; VULVA CANCER; WART VIRUS;

ANOGENITAL WARTS; CERVICAL CANCER; GENITAL WARTS; HPV; HPV VACCINES; HPV-ASSOCIATED DISEASES;

ANUS DISEASES; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VACCINATION; WARTS;

EID: 84888017785     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2013.09.001     Document Type: Review

References (62)

1. Satterwhite C.W., Torrone E., Meites E., et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis 2013, 40(3):187-193.
2. Chesson H.W., Ekwueme D.U., Saraiya M., et al. The cost-effectiveness of male HPV vaccination in the United States. Vaccine 2012, 30:6016-6019.
3. Patel H., Wagner M., Singhal P., et al. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis 2013, 13:39.
4. Hoy T., Singhal P.K., Willey V.J., et al. Assessing incidence and economic burden of genital warts with data from a US commercially insured population. Curr Med Res Opin 2009, 10:2343-2351.
5. Insinga R.P., Dasbach E.J., Myers E.R. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003, 36:1397-1403.
6. Koshiol J.E., Laurent S.A., Pimenta J.M. Rate and predictors of new genital warts claims and genital warts-related healthcare utilization among privately insured patients in the United States. Sex Transm Dis 2004, 31:748-752.
7. Armstrong L.R., Preston E.J., Reichert M., et al. Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle. Clin Infect Dis 2000, 31:107-109.
8. Jemal A., Simard E.P., Dorell C. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. JNatl Cancer Inst 2013, 105(3):175-201.
9. Gillison M.L., Chaturvedi A.K., Lowy D.R. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 2008, 113:3036-3046.
10. Silverberg M.J., Lau B., Justice A.C., et al. Risk of anal cancer in HIV-infected andHIV-uninfected individuals in North America. Clin Infect Dis 2012, 54(7):1026-1034.
11. Piketty C., Selinger-Leneman H., Bouvier A.M., et al. Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the French hospital database on HIV. Clin Oncol 2012, 30:4360-4366.
12. Dolev J.C., Maurer T., Springer G., et al. Incidence and risk factors for verrucae in women. AIDS 2008, 19:1213-1219.
13. Winer R.L., Lee S.K., Hughes J.P., et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003, 157:218-226.
14. Winer R.L., Feng Q., Hughes J.P., et al. Risk of female human papillomavirus acquisition associated with first male sex partner. JInfect Dis 2008, 197(2):279-282.
15. Ho G.Y., Bierman R., Beardsley L., et al. Natural history of cervicovaginal papillomavirus infection in young women. NEngl J Med 1998, 338(7):423-428.
16. Moscicki A.B., Shiboski S., Broering J., et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. JPediatr 1998, 132(2):277-284.
17. Giuliano A.R., Lee J.H., Fulp W., et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet 2011, 377:932-940.
18. Hariri S., Unger E.R., Sternberg M., et al. Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006. JInfect Dis 2011, 204:566-573.
19. Chin-Hong P.V., Vittinghoff E., Cranston R.D., et al. Age-Specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study. JInfect Dis 2004, 190(12):2070-2076.
20. Giuliano A.R., Lu B., Nielson C.M., et al. Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. JInfect Dis 2008, 198:827-835.
21. Shew M.L., Weaver B., Tu W., et al. High frequency of human papillomavirus detection in the vagina before first vaginal intercourse among females enrolled in a longitudinal cohort study. JInfect Dis 2013, 207:1012-1015.
22. Marrazzo JM, Gorgos L. Emerging sexual health issues among women who have sex with women. Curr Infect Dis Rep, in press.
23. Burchell A.N., Coutlée F., Tellier P.P., et al. Genital transmission of human papillomavirus in recently formed heterosexual couples. JInfect Dis 2011, 204(11):1723-1729.
24. Hernandez B.Y., Wilkens L.R., Zhu X., et al. Transmission of human papillomavirus in heterosexual couples. Emerg Infect Dis 2008, 14(6):888-894.
25. Widdice L., Ma Y., Jonte J., et al. Concordance and transmission of human papillomavirus within heterosexual couples observed over short intervals. JInfect Dis 2013, 207(8):1286-1294.
26. Reiter P.L., Pendergraft W.F., Brewer N.T. Meta-analysis of human papillomavirus infection concordance. Cancer Epidemiol Biomarkers Prev 2010, 19(11):2916-2931.
27. Anic G.M., Lee J.H., Stockwell H., et al. Incidence and human papillomavirus (HPV) type distribution of genital warts in a multinational cohort of men: the HPV in men study. JInfect Dis 2011, 204(12):1886-1892.
28. Arima Y., Winer R.L., Feng Q., et al. Development of genital warts after incident detection of human papillomavirus infection in young men. JInfect Dis 2010, 202(8):1181-1184.
29. Garland S.M., Steben M., Sings H.L., et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase iii trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. JInfect Dis 2009, 199:805-814.
30. Winer R.L., Kiviat N.B., Hughes J.P., et al. Development and duration of human papillomavirus lesions after initial infection. JInfect Dis 2005, 191(5):731-738.
31. Woodhall S.C., Jit M., Cai C., et al. Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom. Sex Transm Dis 2009, 36:515-521.
32. Centers for Disease Control and Prevention Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010, 59(RR12):1-110.
33. Ostor A.G. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993, 12(2):186-192.
34. Castle P.E., Schiffman M., Wheeler C.M., et al. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 2009, 113(1):18-25.
35. AJCC cancer staging manual 2010, 165-173. Springer, New York. 7th edition. S.B. Edge, D.R. Byrd, C.C. Compton (Eds.).
36. Hoots B.E., Palefsky J.M., Pimenta J.M., et al. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 2009, 124(10):2375-2383.
37. Centers for Disease Control and Prevention-Division of Cancer Prevention and Control. Cervical Cancer Screening Guidelines for Average-Risk Women. Available at: Accessed August 3, 2012. http://www.cdc.gov/cancer/cervical/pdf/guidelines.pdf.
38. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIVMedicine Association of the Infectious Diseases Society of America. Available at: Accessed August 3, 2013. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf.
39. Kidney Disease, Improving Global Outcomes (KDIGO) Transplant Work Group KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009, 9(Suppl 3):S1-S155.
40. Massad L.S., Einstein M.H., Huh W.K., et al. 2012 ASCCP Consensus Guidelines Conference. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol 2013, 121(4):829-846.
41. University of California San Francisco, Anal Cancer Info: HRA Providers. Availableat: Accessed October 10, 2013. http://id.medicine.ucsf.edu/analcancerinfo/providers.html.
42. Goldstone R.N., Goldstone A.B., Russ J., et al. Long-term follow-up of infrared coagulator ablation of anal high-grade dysplasia in men who have sex with men. Dis Colon Rectum 2011, 54(10):1284-1292.
43. Marks D.K., Goldstone S.E. Electrocautery ablation of high-grade anal squamous intraepithelial lesions in HIV-negative and HIV-positive men who have sex with men. JAcquir Immune Defic Syndr 2012, 59(3):259-265.
44. Nathan M., Hickey N., Mayuranathan L., et al. Treatment of anal human papillomavirus-associated disease: a long term outcome study. Int J STD AIDS 2008, 19(7):445-449.
45. Singh J.C., Kuohung V., Palefsky J.M. Efficacy of trichloroacetic acid in the treatment of anal intraepithelial neoplasia in HIV-positive and HIV-negative men who have sex with men. JAcquir Immune Defic Syndr 2009, 52(4):474-479. [Erratum in J Acquir Immune Defic Syndr 2012;60(3):e105-6].
46. National Cancer Institute: PDQ® Anal Cancer Treatment. Bethesda (MD): National Cancer Institute. Available at: Accessed October 10, 2013. http://cancer.gov/cancertopics/pdq/treatment/anal/HealthProfessional.
47. Markowitz L.E., Dunne E.F., Saraiya M., et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007, 56(RR-2):1-24.
48. Centers for Disease Control and Prevention FDA Licensure of Bivalent Human Papillomavirus Vaccine (HPV2, Cervarix) for Use in Females and Updated HPV Vaccination Recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010, 59:626-629.
49. Centers for Disease Control and Prevention Recommendations on the use of quadrivalent human papillomavirus vaccine in males-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011, 60:1705-1708.
50. Paavonen J., Naud P., Salmerón J., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (Patricia): final analysis of a double-blind, randomized study in young women. Lancet 2009, 374:301-314.
51. Kjaer S.K., Sigurdsson K., Iversen O.E., et al. APooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009, 2(10):868-877.
52. Joura E.A., Leodolter S., Hernandez-Avila M., et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomized clinical trials. Lancet 2007, 369:1693-1702.
53. Palefsky J.M., Giuliano A.R., Goldstone S., et al. HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia. NEngl J Med 2011, 365:1576-1585.
54. FUTURE I/II Study Group Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomized controlled trial. BMJ 2010, 340:1-9.
55. Schiller J.T., Castellsague X., Garland S.M. Areview of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012, 30:123-138.
56. Roteli-Martins C., Naud P., De Borba P., et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother 2012, 8(3):390-397.
57. Centers for Disease Control and Prevention (CDC) Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013-United States. MMWR Morb Mortal Wkly Rep 2013, 62(29):591-595.
58. Hildasheim A., Herrero R., Wacholder S., et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007, 298(7):743-753.
59. Markowitz L.E., Hariri S., Lin C., et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. JInfect Dis 2013, 208(3):385-393.
60. Flagg E.W., Schwartz R., Weinstock H. Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: potential impact of human papillomavirus vaccination. Am J Public Health 2013, 103(8):1428-1435.
61. Bauer H.M., Wright G., Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010. Am J Public Health 2012, 102(5):833-835.
62. Winer R.L., Hughes J.P., Feng Q., et al. Condom use and the risk of genital human papillomavirus infection in young women. NEngl J Med 2006, 354(25):2645-2654.